Discover and read the best of Twitter Threads about #cathywu
Most recents (2)
1/ Happy to share our latest work out today in @Cancer_Cell – a single-cell dissection of the kidney cancer immune microenvironment that uncovers important immune circuitry in advanced disease stages @DanaFarber @DanaFarberNews @harvardmed @broadinstitute
cell.com/cancer-cell/fu…
cell.com/cancer-cell/fu…
2/ The immune microenvironment plays critical roles in controlling the progression of cancer and in response to immunotherapies, yet there are still key open questions regarding the immune cell composition, phenotypic states, and cellular interactions in kidney cancer
3/ To comprehensively dissect the immune microenvironment in kidney cancer, we performed scRNA-seq / scTCR-seq) on 164,722 individual cells from tumor and adjacent non-tumor tissue in patients with ccRCC across disease stages: early, locally advanced, and advanced/metastatic 
1/ Our latest work was just published in @NatureMedicine!
Congratulations to first author Super-Star @BraunMDPhD and to all authors. #CathyWu #SachetShukla @LabSignoretti @VanAllenLab #FreemanLab #SharpeLab
@DanaFarberNews @DanaFarber
#kcsm #KidneyCancer
doi.org/10.1038/s41591…
Congratulations to first author Super-Star @BraunMDPhD and to all authors. #CathyWu #SachetShukla @LabSignoretti @VanAllenLab #FreemanLab #SharpeLab
@DanaFarberNews @DanaFarber
#kcsm #KidneyCancer
doi.org/10.1038/s41591…
2/ Our study analyzes patient samples from 3 prospective clinical trials of PD-1 blockade.
The study includes 592 tumors that were profiled by WES, RNA-seq, and/or IF for CD8+ T cells on samples collected before treatment with Nivolumab (anti-PD1) or Everolimus (mTOR inhibitor)
The study includes 592 tumors that were profiled by WES, RNA-seq, and/or IF for CD8+ T cells on samples collected before treatment with Nivolumab (anti-PD1) or Everolimus (mTOR inhibitor)
3/ We evaluated genomic correlates of response to PD-1 inhibitors in ccRCC.
Molecular features that had been previously suggested to correlate with outcomes (e.g. TMB, NeoAg load) were not found to be predictive of benefit from PD-1 blockade.
Molecular features that had been previously suggested to correlate with outcomes (e.g. TMB, NeoAg load) were not found to be predictive of benefit from PD-1 blockade.
